Serologicals Corporation (SERO) Agrees To Acquire Cytomyx Ltd.; Expands Drug Discovery Screening Portfolio
3/14/2006 11:11:15 AM
ATLANTA--(BUSINESS WIRE)--March 14, 2006--Serologicals Corporation (NASDAQ: SERO) announced today a definitive agreement to acquire Cytomyx Ltd., a wholly owned subsidiary of Cytomyx Holdings Plc (AIM: CYX). Based in Cambridge, U.K., Cytomyx Ltd. is a leading provider of ion channel cell lines and drug discovery services. With 23 distinct ion channel cell lines commercially available, and more in its pipeline, Cytomyx Ltd. offers the largest portfolio of distinct ion channel cell lines in the marketplace today.
comments powered by